Hanadi Jabado is a start-up advisor, angel investor and non-executive who is passionate about entrepreneurship and innovation. She supports early-stage businesses across a range of sectors with a focus on healthcare and deep-tech. Her ability to act as a technology translator and to align vision and strategy with operational constraints are key to her high success rate. Hanadi’s experience in developing innovation clusters is globally recognised. She has helped set-up entrepreneurial ecosystems in the Middle East, Russia and China.
In 2012, Hanadi was the driving force behind the creation of Accelerate Cambridge, which contributed to the Cambridge entrepreneurial cluster by providing help and support to innovators and entrepreneurs. Hanadi has supported the creation and scale-up of over 180 early stage ventures, building a portfolio of an estimated collective value of £1.5bn and over £300m of risk capital raised. In early 2016, Hanadi was appointed Executive Director of the Entrepreneurship Centre at the Cambridge Judge Business School.Since January 2019, Hanadi has centred her work around the investment needs of early stage ventures and more specifically, the funding gap in the UK for ambitious life-sciences and biotech businesses. This led to the creation of CMS Ventures, and Hanadi’s appointment as its managing director. CMS Ventures is an early-stage investor based in Cambridge investing in Biotech; Life Sciences start-ups in the UK with a focus on the 4Ds (Drugs, Devices, Diagnostics, and Digital) and privileged access to international markets, in particular China. In September 2021 Hanadi was appointed to the Innovate UK innovation loans Credit Committee as an external member. Her stakeholder management skills and her clear leadership make her an effective Chair allowing her to develop a portfolio of non-executive directorships alongside her executive roles. She is a seasoned start-up advisor, angel investor and non-exec.
Most recently she has become a Managing Partner for Sana Capital Limited, an investment fund adviser which aims to drive innovation that can heal the world, demystifying deep tech at scale to drive positive change. Born in Lebanon and raised in France, she is fluent in English, French and Arabic and speaks another four languages. She lives in Cambridge with her four children.
Testimonials for Hanadi
“I worked with Hanadi from the very inception of our company. She helped as a mentor in guiding me through being a first time CEO, understanding the fundraising process with Venture Capital partners and ensuring good governance structures at the very early stages. As we grew the company she became instrumental in helping me create our strategic vision and understanding our ability to scale our platform. I would highly recommend her as someone with clarity of thought and the ability to assist companies in the deep tech sector.”
Dr Muhunthan Thillai(CEO, Qureight)
“I worked with Hanadi for a number of years as part of the board of Cambridge Spark where she was the chair person. She’s supported me in introducing appropriate governance, hiring a CFO, navigating difficult economical climates and developing a winning go-to-market strategy. Her support has enabled Cambridge Spark to accelerate its growth, scale and reach profitability.”
Dr. Carina Tyrrell is a British-Swiss venture capital investor, passionate about investing in innovative technology startups that have the potential to revolutionize industries and change the world.
Formerly Investor and Chief of Staff to ex-President of Samsung, she led the health and life-science investment thesis at $600m deeptech fund Walden Catalyst. Prior to that, she worked as an analyst at Goldman Sachs Healthcare Investment Research.
Carina has a background as a medical doctor and public health physician scientist at Oxford and Cambridge Universities, where she remains an Academic Clinical Fellow at the MRC Epidemiology Unit, Cambridge University. In 2021, she featured on the front page of The Times for her work to help deliver the Oxford–AstraZeneca COVID-19 vaccine.
A Governor for Cambridge University Hospitals, and President’s Fellow at Murray Edwards College, Cambridge University, Carina has also worked with local and national government and international organisations, including the UK Government and the World Health Organization.
Carina holds a first-class degree in Natural Sciences (MA), a Bachelor of Medicine and Bachelor of Surgery (MB BChir), and a Master of Public Health with distinction (MPH) from Cambridge University.
She has appeared on BBC News, ITV News, Sky News, Radio 4, and has been featured in The Times, Daily Telegraph, and Business Insider, sharing her insights and expertise related to healthcare, technology, and venture capital investing.
Jolyon Martin is an accomplished entrepreneur, mentor, and non-executive director whose background and skills place him at the interface of fundamental science and its commercial applications. He is passionate about the people behind the projects and supports early-stage founders across the globe in their mission to translate their ideas into reality.
Jolyon’s PhD at the University of Cambridge was to translate a gold-standard human drug discovery platform into an animal health application. This work led to first author papers and the core intellectual property, on which he is inventor, of what would become PetMedix Ltd. Spinning out PetMedix as a founder in 2017, Jolyon moved into a commercial role in the company and led on licensing and partnering deals, including those with the two largest global animal health companies. He was intimately involved in the $50M raised by the company and completed the founder cycle in 2023 when PetMedix was acquired as part of a successful exit.
Beyond his role at PetMedix, Jolyon advises the British Government’s Department for Business and Trade. As part of the Global Entrepreneur Programme, he helps international founders looking to relocate to the UK with a blend of practical and strategic advice in order to facilitate their soft landing, and ultimately success. He also sits on the board of ArkVax, an innovative early-stage animal health company, and is helping guide their journey.
A big believer in ‘pay it forwards’, Jolyon has been informally and formally mentoring early-stage founders for a number of years, including on the Nucleate programme in 2023. Outside of work, Jolyon trained in ballet for ten years and then ballroom dancing for twelve. Whilst he has retired from dancing, Jolyon continues to keep very active across a number of sports and disciplines. Fortunate enough to have lived across three continents, travel remains a passion, and is helped by the fact he speaks French and Spanish alongside his native English.
Now a partner at Sana Capital, Jolyon is looking to turn his skills and experience as a founder to identifying and supporting the next wave of companies looking to translate groundbreaking science and technology into world-changing innovations.
National political journalist and Chair, National Brain Appeal
National political journalist and Chair, National Brain Appeal
Jackie Ashley was a national political journalist for more than thirty years, working for the BBC, ITN, Channel 4 News, the Statesman and the Guardian. She was President of Lucy Cavendish College, University of Cambridge from 2015 – 2018 and is now an Honorary Fellow of the College and Chair of the Lucy Cavendish Fiction Prize. During her time at Cambridge, Jackie put in place several initiatives to encourage young women to consider a career in tech. She now chairs the National Brain Appeal, supporting research into all aspects of brain disease; is an Ambassador for the Carers Trust; a trustee of the Hansard Society and a member of the Royal Television Society News and Current Affairs awards Committee. Jackie also works as a media consultant.
Dr David Brown is Co-founder and Chair of the Board of Healx Ltd, a Cambridge University spinout company which uses Machine Learning to find treatments for children with rare diseases. He was also co-founder of the antibody company Crescendo Biologics. He was listed in the Maserati 100 UK Innovators/ Entrepreneurs list for 2019.
Earlier in his career he pursued medical research in the pharmaceutical industry. Whilst at Pfizer he was named co-inventor on the patent for Viagra, and for 8 years he led the team developed Viagra through to proof of clinical efficacy in male impotence. Relpax (migraine) and Revatio (Pulmonary Arterial Hypertension) also came from his team and together these drugs have sales of over $40bn. While at Roche in Switzerland, he was a Director of the company and, as Global Head of Drug Discovery, he had responsibility for productivity of over 2000 scientists at Roche’s five research sites in the USA, Europe and Asia.
Senior Vice President, Business Development Operations, AstraZeneca
Senior Vice President, Business Development Operations, AstraZeneca
Shaun Grady has global responsibility for Business Development Operations at AstraZeneca, leading the company’s transaction execution, due diligence and Alliance and Integration Management function including licensing and partnering, M&A, externalisation and divestments. Shaun was appointed to his current role in 2013. Prior to this, he was Vice President, Strategic Partnering & Business Development (2010 – 13) and Vice President, Corporate Business Development (2006 – 10). Shaun originally joined ICI as an attorney and held positions in the pharmaceuticals, petrochemicals, and legal departments. Following the demerger from ICI, he was appointed Assistant General Counsel, Corporate for Zeneca Group PLC. Shaun worked on the merger of Astra and Zeneca, the merger of Zeneca Agrochemicals with Novartis Agribusiness to form Syngenta, and the creation of Avecia. Shaun also worked on the acquisition of Cambridge Antibody Technology (CAT) and later MedImmune and led the acquisition of Amylin, and subsequent buy-out of Bristol-Myers’ Squibb’s interest in the AZ – BMS Diabetes Alliance. More recently Shaun led the transaction team for AZ’s global ADC collaboration with Daiichi Sankyo for DS 8201. Shaun has led AZ’s recent externalisation and divestment programme involving transactions with Aspen, Grunenthal, Cheplapharm, Recordati and Covis. Shaun is a Fellow in Entrepreneurship at Cambridge University Judge Business School, a Fellow at Lucy Cavendish College and is a member of the Board of Cambridge United Football Club, Cambridge Arts Theatre, Healx and Prostate Cancer Research Centre. Based in Cambridge, Shaun enjoys rugby and soccer, and occasionally turns his hand to sports writing.
Darrin has built an international reputation as a scientific and business innovator across the life sciences sector. With 30 years of experience in the translation of science into industrial application and commercial success, Darrin has grown, or invested in many enterprises and helped to secure significant sums of private and public funding and commercial deals. Darrin is currently CEO, Investor and Director of Mogrify a UK biotechnology company that has developed a revolutionary direct cell conversion and maintenance platform technology that aims to transform the development of ex vivo cell therapies and pioneer a new class of in vivo regenerative therapies. In parallel, he is Chairman of CELIXIR PLC a regenerative medicine company founded by Nobel Prize winner Sir Martin Evans, whose lead product HeartCel has begun a Phase 2 clinical trial to improve the outcomes of patients undergoing coronary artery bypass graft surgery. Prior to this Darrin led Horizon Discovery Group Plc, a gene-editing market leader, from a $200k seed funding in March 2008 to an IPO of $113 million on AIM in March 2014. Darrin has won numerous awards and accolades in recognition of his industry, enterprise and philanthropic efforts including a Queens Award for Enterprise Promotion in 2016 and in 2018 he was made an Officer of the Order of the British Empire (OBE). He is an active and passionate philanthropist. Darrin has established a 10-year endowment of the Professor Christopher R Lowe Carpe Diem Enterprise Fund that supports hundreds of young students, entrepreneurs, and businesses with mentoring and financial help. He also hold several honorary and academic positions including Enterprise Fellow at the Department of Chemical Engineering and Biotechnology, University of Cambridge, Honorary Fellow of the Cambridge Judge Business School and Honorary Visiting Fellow at the School of Environmental and Life Science at the University of Salford.
Amali de Alwis is CEO at Subak. Subak’s mission is to accelerate climate action by funding and scaling a global ecosystem of organisations and individuals that use data and tech to create systemic change in policy and behaviour.
Outside of the day job, Amali is a Board member at Ada National College for Digital Skills, the Raspberry Pi Foundation, Unboxed 2022, and the abrdn Foundation. She is a venture partner at Sana Capital Management, was a founding member at Tech Talent Charter, and was named as ‘The most Influential woman in UK IT’ by Computer Weekly. She was awarded an MBE in 2019 in the New Year’s Honours list for Services to Diversity and Training in the Tech Industry.
Jeanette is a tech sector CEO, blue-chip business leader, digital Innovation and transformation executive. She is the founder and CEO of Tech Nordic Advocates, Northern Europe’s largest and only pan-Nordic/Baltic (not-for-profit) tech/start-up ecosystem network. Additionally, she works as business, government and diplomatic advisor, NED, mentor, innovation lecturer, conference chair/keynote as well as fintech and start-up investor and landscape expert. She has a 25-year track record of building, growing & advising start-ups to PLCs in the fast-paced digital, tech and innovation space. Jeanette is passionate about what tech can do for businesses and people, she thrives on challenges, high-speed, complex environments and bringing the best people together to make things happen. She was recognised by Queen Elizabeth II at Buckingham Palace for her contribution to London’s start-up ecosystem and voted ‘Inspirational Woman’, City of London, in 2018.
Roger completed his education in Belgium, with an MS in Aerospace Engineering from University of Liège and a PhD in Computational Mechanics from University of Louvain. He then transitioned to business taking an MBA in International Business from Sacred Heart University, CT, USA and complementing his base education with multiple executive courses in Entrepreneurship and business at MIT and Harvard.
Roger is a serial entrepreneur: he co-founded e-Xstream engineering in 2003 and grew it to become a leader in advanced material modeling, staying on as the CEO until 2020. In 2012, the company exited to MSC Software, which Roger was the president of in 2020 and 2021. He also co-founded a new startup focusing on In-Silico Medicine in October 2022.
Roger is an active business angel with several investments in Start-ups and scale-ups in Health Tech and other tech areas. He also serves as a board member in a variety of companies.
In his free time, Roger enjoys various outdoor sports, such as scuba diving, sailing, snowboarding, swimming and cycling.
Sana Capital™ Limited is an appointed representative of Sapia Partners LLP, which is authorised and regulated by the Financial Conduct Authority (FRN: 550103). The services offered on this website are intended for professional investors only.